Rani Therapeutics Holdings (RANI) Research & Development (2020 - 2026)

Rani Therapeutics Holdings has reported Research & Development for 7 years, with the latest figure at $5.0 million in Q2 2026.

• On a quarterly basis, Research & Development fell 8.86% year-over-year to $5.0 million in Q2 2026; TTM through Jun 2026 was $18.3 million, a 26.93% decrease from a year earlier, with the FY2025 full-year figure at $20.2 million, down 24.27% from the prior year.
• Research & Development was $5.0 million for Q2 2026 at Rani Therapeutics Holdings, down from $5.2 million in the prior quarter.
• The five-year high for Research & Development was $11.2 million in Q3 2023, with the low at $3.2 million in Q3 2025.
• Average Research & Development over 5 years is $7.4 million, with a median of $7.2 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Research & Development soared 153.47% in 2022, then tumbled 47.81% in 2025.
• Over 5 years, Research & Development stood at $10.4 million in 2022, then dropped by 26.77% to $7.6 million in 2023, then fell by 10.47% to $6.8 million in 2024, then slipped by 27.91% to $4.9 million in 2025, then rose by 2.2% to $5.0 million in 2026.
• The last three Research & Development figures came in at $5.0 million (Q2 2026), $5.2 million (Q1 2026), and $4.9 million (Q4 2025), per Business Quant data.